...
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Posts by Jitendra

Home » Articles Posted by Jitendra (Page 25)
28 Feb
Press Release

Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido™ (lidocaine topical system) 1.8% for PHN Pain

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and Drug Administration (FDA) for ZTlido™...

Read more

14 Nov
Press Release

SCILEX PHARMACEUTICALS, SORRENTO THERAPEUTICS’ SUBSIDIARY, FILES MARKETING AUTHORIZATION APPLICATION IN THE EUROPEAN UNION FOR ZTLIDO™

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, November 14th, 2017 /GlobalNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that Scilex Pharmaceuticals Inc. ("Scilex"), a majority-owned subsidiary of Sorrento, filed the European Marketing Authorization Application (MAA) for its...

Read more

12 Sep
Press Release

FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, Sept. 12, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration ("FDA")...

Read more

31 Aug
Press Release

Sorrento Therapeutics’ Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido™

  • July 15, 2021
  • Posted by Jitendra
- ZTlido™ demonstrated superior adhesion as compared to the reference product in the EU SAN DIEGO, June 14, 2017 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced...

Read more

30 Aug
Press Release

Sorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA...

Read more

09 Jan
Press Release

Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

  • July 15, 2021
  • Posted by Jitendra
- Marketing Authorization Application is expected to be filed in mid-2017 NEWS PROVIDED BY Sorrento Therapeutics, Inc. Jan 09, 2017, 09:00 ET SAN DIEGO, Jan. 9, 2017 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics,...

Read more

05 Dec
Press Release

Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

  • July 15, 2021
  • Posted by Jitendra
- 505(b)(2) NDA resubmission is expected in mid-2017 December 5, 2016 SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study...

Read more

08 Nov
Press Release

Sorrento Therapeutics Closes Acquisition of Scilex

  • July 15, 2021
  • Posted by Jitendra
November 8, 2016 SAN DIEGO, Nov. 8, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento") and Scilex Pharmaceuticals Inc. ("SCILEX") announced today the closing of a transaction by which Sorrento acquired a majority of SCILEX. ...

Read more

22 Apr
Press Release

SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized

  • July 15, 2021
  • Posted by Jitendra
MALVERN, Pa.--(BUSINESS WIRE)--SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, reported data on how healthcare providers are currently treating patients with post-herpetic neuralgia...

Read more

23 Feb
Press Release

SCILEX Pharmaceuticals Announces Senior Industry Hires

  • July 15, 2021
  • Posted by Jitendra
Malvern, PA, February 23, 2016 – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of medical and regulatory affairs...

Read more

«‹23242526›
Close
Recent Posts
  • Nasdaq_Gloperba03
    Gloperba Launch – Nasdaq-2024
    July 10, 2024 No Comments
  • A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain
    June 14, 2024 No Comments
  • Gout Awareness Day – May 22
    May 20, 2024 No Comments
  • Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis
    March 14, 2024 No Comments
  • Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch
    March 14, 2024 No Comments

scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2024 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info